BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 20370678)

  • 1. Adipocytokines in nonalcoholic fatty liver disease: key players regulating steatosis, inflammation and fibrosis.
    Tilg H
    Curr Pharm Des; 2010 Jun; 16(17):1893-5. PubMed ID: 20370678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leptin: the prototypic adipocytokine and its role in NAFLD.
    Procaccini C; Galgani M; De Rosa V; Carbone F; La Rocca C; Ranucci G; Iorio R; Matarese G
    Curr Pharm Des; 2010 Jun; 16(17):1902-12. PubMed ID: 20370676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines.
    Polyzos SA; Kountouras J; Zavos C
    Curr Mol Med; 2009 Apr; 9(3):299-314. PubMed ID: 19355912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver fibrogenesis and metabolic factors.
    Anty R; Lemoine M
    Clin Res Hepatol Gastroenterol; 2011 Jun; 35 Suppl 1():S10-20. PubMed ID: 21742296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease.
    Stojsavljević S; Gomerčić Palčić M; Virović Jukić L; Smirčić Duvnjak L; Duvnjak M
    World J Gastroenterol; 2014 Dec; 20(48):18070-91. PubMed ID: 25561778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of disease: adipocytokines and visceral adipose tissue--emerging role in nonalcoholic fatty liver disease.
    Schäffler A; Schölmerich J; Büchler C
    Nat Clin Pract Gastroenterol Hepatol; 2005 Jun; 2(6):273-80. PubMed ID: 16265231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Adipocytokines and nonalcoholic steatohepatitis].
    Lăcătuşu C; Mihai B; Mihai C; Cijevschi-Prelipcean C; Graur M
    Rev Med Chir Soc Med Nat Iasi; 2009; 113(2):345-52. PubMed ID: 21495339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Adipocitokines and nonalcoholic steatohepatitis].
    Lăcătuşu C; Mihai B; Cijevschi-Prelipcean C; Mihai C; Graur M
    Rev Med Chir Soc Med Nat Iasi; 2008; 112(4):882-9. PubMed ID: 20209757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammatory mediators of hepatic steatosis.
    Hijona E; Hijona L; Arenas JI; Bujanda L
    Mediators Inflamm; 2010; 2010():837419. PubMed ID: 20300479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The role of adipokines and insulin resistance in the pathogenesis of nonalcoholic fatty liver disease].
    Orlik B; Handzlik G; Olszanecka-Glinianowicz M
    Postepy Hig Med Dosw (Online); 2010 May; 64():212-9. PubMed ID: 20498498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retinol-binding protein 4 and new adipocytokines in nonalcoholic fatty liver disease.
    Tönjes A; Blüher M; Stumvoll M
    Curr Pharm Des; 2010 Jun; 16(17):1921-8. PubMed ID: 20370670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adiponectin: a key player in obesity related disorders.
    Matsuzawa Y
    Curr Pharm Des; 2010 Jun; 16(17):1896-901. PubMed ID: 20370675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gender-specific differences in adipose distribution and adipocytokines influence adolescent nonalcoholic fatty liver disease.
    Ayonrinde OT; Olynyk JK; Beilin LJ; Mori TA; Pennell CE; de Klerk N; Oddy WH; Shipman P; Adams LA
    Hepatology; 2011 Mar; 53(3):800-9. PubMed ID: 21374659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic fatty liver disease: from steatosis to cirrhosis.
    Farrell GC; Larter CZ
    Hepatology; 2006 Feb; 43(2 Suppl 1):S99-S112. PubMed ID: 16447287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adipocytokines and hepatocellular carcinoma.
    Wieser V; Moschen AR; Tilg H
    Dig Dis; 2012; 30(5):508-13. PubMed ID: 23108307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C.
    Rafiq N; Younossi ZM
    Expert Rev Gastroenterol Hepatol; 2008 Apr; 2(2):207-15. PubMed ID: 19072356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy.
    Tsochatzis EA; Papatheodoridis GV; Archimandritis AJ
    Mediators Inflamm; 2009; 2009():831670. PubMed ID: 19753129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association between adipocytokines and biomarkers for nonalcoholic fatty liver disease-induced liver injury: a study in the general population.
    Zelber-Sagi S; Ratziu V; Zvibel I; Goldiner I; Blendis L; Morali G; Halpern Z; Oren R
    Eur J Gastroenterol Hepatol; 2012 Mar; 24(3):262-9. PubMed ID: 22246329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular pathways of nonalcoholic fatty liver disease development and progression.
    Bessone F; Razori MV; Roma MG
    Cell Mol Life Sci; 2019 Jan; 76(1):99-128. PubMed ID: 30343320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The epidemiology, pathogenesis and histopathology of fatty liver disease.
    Levene AP; Goldin RD
    Histopathology; 2012 Aug; 61(2):141-52. PubMed ID: 22372457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.